Amgen INC Form 4 insider transactions

David M. Reese, EVP & Chief Technology Officer of Amgen, reports acquiring 12,407 shares of common stock on March 6, 2024.

Amgen's SVP of Human Resources, Derek Miller, reports acquiring 1,311 shares of common stock on March 6, 2024, bringing his total holdings to 8,863 shares.

Rachna Khosla, SVP of Business Development at Amgen, reports acquiring 1,256 shares of common stock on March 6, 2024.

Nancy Grygiel, SVP & CCO of Amgen, reports changes in her beneficial ownership of Amgen stock, including acquisitions and holdings in a 401(k) plan.

Peter H. Griffith, EVP & CFO of Amgen, reports acquiring 10,338 shares of common stock on March 6, 2024.

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reports the acquisition of 11,760 shares of common stock and holdings of 39,925 shares, including restricted stock units (RSUs) and dividend equivalents (DEs).

Murdo Gordon, EVP at Amgen, reports acquiring 12,924 shares of Amgen common stock on March 6, 2024, bringing his total holdings to 57,569 shares.

Matthew C. Busch, VP of Finance & CAO at Amgen, reports the acquisition of 418 shares of common stock on March 6, 2024.

Amgen's CEO, Robert Bradway, reports acquiring 41,133 shares of common stock on March 6, 2024, bringing his total holdings to 683,910 shares.